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Abstract
Background: Neurofeedback (NF) has gained increasing interest among non-pharmacological treatments for
Attention Deficit Hyperactivity Disorder (ADHD). NF training aims to enhance self-regulation of brain activities. The
goal of the NEWROFEED study is to assess the efficacy of a new personalized NF training device, using two different
protocols according to each child’s electroencephalographic pattern, and designed for use at home. This study is a
non-inferiority trial comparing NF to methylphenidate.
Methods: The study is a prospective, multicentre, randomized, reference drug-controlled trial. One hundred
seventy-nine children with ADHD, aged 7 to 13 years will be recruited in 13 clinical centres from 5 European
countries. Subjects will be randomized to two groups: NF group (Neurofeedback Training Group) and MPH group
(Methylphenidate group). Outcome measures include clinicians, parents and teachers’ assessments, attention
measures and quantitative EEG (qEEG). Patients undergo eight visits over a three-month period: pre-inclusion visit,
inclusion visit, 4 “discovery” (NF group) or titration visits (MPH group), an intermediate and a final visit. Patients will
be randomized to either the MPH or NF group. Children in the NF group will undergo either an SMR or a Theta/
Beta training protocol according to their baselineTheta/Beta Ratio obtained from the qEEG.
Discussion: This is the first non-inferiority study between a personalized NF device and pharmacological treatment.
Innovative aspects of Mensia Koala™ include the personalization of the training protocol according to initial qEEG
characteristics (SMR or Theta/Beta training protocols) and an improved accessibility of NF due to the opportunity to
train at home with monitoring by the clinician through a dedicated web portal.
Trial registration: NCT02778360. Date registration (retrospectively registered): 5-12-2016. Registered May 19, 2016
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Background
Attention deficit hyperactivity disorder (ADHD) is
one of the most common childhood and adolescent
psychiatric disorders with prevalence rates ranging
from 5 to 7% worldwide [1, 2]. It is a developmental
disorder characterized by difficulties in attention,
hyperactivity and impulsivity with significant impair-
ment across youth’s social, cognitive, academic, behav-
ioral, and familial functioning [3].
Multimodal approaches are recommended for the treat-
ment of ADHD, consisting of combination of pharmaco-
logical and psychological treatments [4]. Pharmacological
treatments are efficacious, and form the most frequent and
convenient treatment for ADHD in developed countries
[5]. However, their benefits may be limited in various
situations because of adverse effects, poor adherence or
negative medication-related attitudes from parents and cli-
nicians [5, 6]. Thus, it is important to consider non-
pharmacological treatments such as psychological and re-
mediation-based strategies. Among non-pharmacological
interventions, neurofeedback (NF) has been considered a
promising ADHD treatment strategy [6–10].
NF is a computer-based behaviour training enabling a
person to self-regulate aspects of brain activity [11, 12],
which are commonly measured with electroencephalog-
raphy (EEG). The incoming EEG signal is compared to a
predetermined training goal and this information is then
presented to the subject in real-time and reinforced with
visual or auditory feedback [13]. The achievement of the
target parameter is associated with rewards according to
the principles of operant conditioning or skill learning. In
practical terms, this takes the form of a computer game in
which children obtain rewards when their brain activity
changes in the desired direction. Repeated training is
thought to foster automatization of the learned process
with subsequent changes at the behavioural level [14].
The following training protocols are considered stand-
ard NF procedures in ADHD [15]: 1) Theta/beta ratio
(TBR) down-regulation, 2) increase in Sensori-Motor
Rythm (SMR) and 3) training of Slow Cortical Potentials
(SCP). The TBR down-regulation protocol involves redu-
cing theta activity (4–8 Hz) while increasing beta activity
(16–20 Hz). It is based on increased slow frequency os-
cillations (theta) and decreased high frequency oscilla-
tions (beta) in subjects with ADHD [16]. However, more
recent studies are not in favor of consistent theta or
theta/beta increases in ADHD [17] or suggest they may
affect a subgroup of 25–40% of patients [18].
The increase in SMR, a low beta frequency observed
over the sensory-motor cortex (SMR; 12–15Hz) has been
related to improved hyperactivity and distractibility as well
as to a better sleep quality [19, 20]. NF training of slow
cortical potentials (SCP) is aimed at learning bidirectional
regulation of cortical excitability [21, 22]. The rationale for
SCP training is the reduced contingent negative variation
(CNV) in ADHD, an event-related potential component
associated with cognitive anticipation [23].
NF efficacy in ADHD is a hotly-debated subject [6, 8,
10, 24, 25]. Although several meta-analyses of NF report
satisfactory and good clinical effects when based on par-
ents’ assessments [26], other studies have reported no sig-
nificant effects when “probably blinded ratings” were
considered [8, 27]. A network meta-analysis showed su-
periority of stimulants combined with behavioral therapy
or with non-stimulants in comparison with neurofeedback
on a dichotomous outcome of ADHD core-symptoms or
global functioning [28].There were no differences of ac-
ceptability in this meta-analysis between NF and stimu-
lants. However, comparative evidence was likely to be
limited by the combined analysis of both methylphenidate
(MPH) and amphetamines and by the use of a categorical
and global outcome. A more recent meta-analysis in-
cluded treatment effects at follow-up. Within-group NF
effects were of medium effect size on inattention at post-
treatment with increasing ES at follow-up and of medium
effect size on hyperactivity/impulsivity at both endpoint
and follow-up. Medication showed large ES for inattention
and medium ES for hyperactivity/impulsivity at both end-
points [29].
Analysis of NF effectiveness is also affected by the di-
versity of training procedures and methodological issues.
In this regard, novel aspects of the NEWROFEED study
include a personalized selection of training protocols to
match individual EEG characteristics (e.g. based on the
individual theta/beta ratio), and improved access
through parent-managed training at home coupled with
consistent monitoring.
The aim of the NEWROFEED study is to assess the ef-
ficacy of a new personalized neurofeedback training de-
vice, Mensia Koala™, designed for individualized use at
home, through a non-inferiority trial comparing EEG-
NF to methylphenidate in children with ADHD.
Methods
The study is a prospective, multicentre, randomized, ref-
erence drug-controlled trial in 179 ADHD children. Sub-
jects are randomized in two groups: NFT group
(Neurofeedback Training Group) and MPH group (Me-
thylphenidate group). The study is drug reference-con-
trolled in a 3/2 ratio that maximizes exposure to NFT
without impacting power
Objectives
The main objective of this study is to demonstrate the
non-inferiority of a personalized Neurofeedback Train-
ing device (i.e. Mensia Koala™) versus Methylphenidate
(Medikinet®) in the treatment of children with ADHD.
The primary endpoint is the change from baseline
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(inclusion visit) to end of treatment (last visit) in the
clinician-rated ADHD-RS IV total score [30].
The secondary objectives are to investigate whether
there are effects on:
– Clinician ADHD RS IV Inattention and
Hyperactivity Scores
– Clinical responders (defined as patients reducing
their symptoms by more than 25% from their
baseline [31]) vs. non-responders
– Parent’s ADHD RS IV Total, Inattention and
Hyperactivity Scores
– Teacher’s ADHD RS IV Total, Inattention and
Hyperactivity Scores, and Strengths and Difficulties
Questionnaire (SDQ)
– Executive Function as measured by the Behavior
Rating Inventory of Executive Function (BRIEF)
– Clinical Global Impression (CGI) scale (both
components: Severity, CGI-S, and Improvement,
CGI-I)
– The Conners Continuous Performance Test 3rd
Edition (Conners CPT 3) [32]
– EEG signature evaluation and normalization
including individual alpha peak frequency,
Quantitative EEG (qEEG) outcome and learning
biomarkers.
We hypothesized that the decrease in the Clinician
ADHD RS IV total score between baseline (at the inclu-
sion visit) and end of treatment (at final visit) is not su-
perior (i.e. not larger) in the MPH group compared to
the NF group.
Subjects
The study population includes children diagnosed with
inattentive or combined presentation of ADHD. One
hundred seventy-nine children aged between 7 to 13
years will be recruited. Clinical diagnosis of ADHD is
made by a psychiatrist using Kiddie-SADS (K-SADS)
[33], a semi-structured interview with the child and his/
her parents.
Thirteen clinical centres from 5 European countries
(Belgium, France, Germany, Spain, and Switzerland) will
participate in the study.
Eligibility criteria
A subject is eligible for inclusion in this study only if all
of the following criteria apply:
– Children or adolescents (male or female) aged 7–13
years
– ADHD diagnosis positive with K-SADS
– Patient having already had non-pharmacological
treatment or psychoeducation for ADHD
– Signature of informed consent form by parent and
child
– Wireless internet connection at home
A subject is not eligible for inclusion in this study if
any of the following criteria apply:
– ADHD with hyperactive/impulsive presentation
without inattention component
– Established diagnostic of epilepsy, autism,
schizophrenia or other neurological disorders
– Major psychiatric disorder other than ADHD
diagnosed with Kiddie-Sads such as autism,
schizophrenia, severe generalized anxiety disorder,
major depression, or tics
– Patient having already been treated with psycho-
active drug (MPH and others) or EEG-NF for
ADHD
– Unable to use the NF device (tablet use and/or
headset set-up and/or understanding instructions)
according to the investigator
– Medical disorder requiring systemic chronic
medication with confounding psychoactive effects
– IQ < 80 using the 3 subtest form of the WASI or the
WISC
– Plans to move requiring school change during the
next 6 months
– Plans to start other ADHD treatment, including
psychotherapy, cognitive behaviour training in the
next 6 months
– Patient with chronic medical illness, such as seizure,
cardiac disorders, untreated thyroid disease,
glaucoma
– Significant suicidal risk based on clinical opinion
Study flow
Patients undergo eight visits over three months: pre-in-
clusion visit, inclusion visit (D0), four discovery (NFT
group) or titration visits (MPH group), an intermediate
visit (D60) and a final visit (D90). Patients are random-
ized to either the MPH or NFT group at inclusion visit
and treated until final visit.
Figure 1 describes the design of the study and Table 1
shows the list of all assessments and their respective
time of acquisition.
At pre-inclusion, children are screened and diagnosed
to confirm their ADHD status. This evaluation includes
the K-SADS interview [33], a semi-structured diagnostic
interview designed to assess current and past episodes of
psychopathology in children and adolescents according
to DSM-IV criteria. At this visit cognitive function is
tested with the WISC IV (Wechsler Intelligence Scale
for Children) or with the WASI (Wechsler Abbreviated
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Scale of Intelligence; [34]) unless results from an IQ-test
accomplished in the last 18 month are available.
Scales are filled out by one parent and it is requested
that ratings are made by the same person throughout all
assessment visits.
The description of the various visits is summarized
in Table 1.
The inclusion visit includes the collection of demo-
graphic data, medical/surgical history, concomitant
medication and a medical examination. Moreover, the
following scales are completed: the ADHD-RS in its 3
versions (clinician, parents and teacher), the CGI-S, the
C-SSRS, the SDSC, the SDQ (by parents and teachers)
and the BRIEF. During the same visit a CPT and a qEEG
are carried out (see Table 1).
qEEG is recorded with the same equipment used for
neurofeedback training. The recording is performed
under resting state conditions (while the subject is not
performing any task) with one record of eyes-opened
and another record of eyes-closed conditions (2-min
each). At this visit a treatment group is assigned, accord-
ing to the randomization list (NFT or MPH group).
Two distinct neurofeedback protocols are imple-
mented in the application: the first is based on the
down-training of the theta/beta ratio (noted “TBR”) in
fronto-central areas, the second aims at enhancing the
Sensori-Motor Rhythms (also called “SMR”) in central
regions. The purpose of the first assessment is to deter-
mine the training protocol that will give the best result
in the reduction of the ADHD symptoms. For that pur-
pose, the theta/beta ratio is computed and compared to
a threshold value equal to 4,5. Patients whose TBR is
above 4,5 will follow a TBR down-training protocol
whereas patients whose TBR is below 4.5 will follow a
SMR up-training protocol. The decision made by the ap-
plication has to be validated by the clinician. Both proto-
cols give access to the same workflow in the application.
Thus, children in the NFT group undergo either SMR or
Theta/Beta training protocol according to their Theta
Beta Ratio obtained during the qEEG.
During the four “discovery” (NF group) or titration visits
(MPH group), CGI-I, and CGI-S, C-SSRS and SDSC are
completed. Concomitant medications and adverse events
are collected following the delivery of therapeutic units
(MPH group) or training with the investigator (NF group).
During an intermediary visit the 3 versions of the
ADHD-RS, CGI-I and CGI-S, C-SSRS and SDSC are
completed and a qEEG is also done (see Table 1).
The final visit (three months after inclusion) includes
the ADHD-RS in its 3 versions, the CGI-I and CGI-S
score, the C-SSRS, the SDSC, the SDQ (by parents and
teacher) and the BRIEF. This visit also comprises a CPT
(CPT-3) and a qEEG (see Table 1).
Interventions
Neurofeedback group
The Mensia Koala™ medical device is composed of a
software for personalized brain rehabilitation at home
Training (“ADHD@Home NFT v1.1”) connected to an
EEG amplifier and to an EEG cap. A baseline assessment
starts every NF session; the data acquired on the tablet
is automatically synchronized with a cloud server in
order to make the personalized brain rehabilitation data
retrievable on a secured web portal (“ADHD@Home
Fig. 1 Flow chart study design
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Follow-Up v1.1”) (see Fig. 2). The software is used to
record data from 8 AgCl scalp electrodes located at
standard 10–20 locations (Fpz, Fz, F3, F4, Cz, C3, C4,
and Pz) referenced and grounded to the left and right
earlobes, respectively. The signals are amplified and digi-
talized over 24 bits 512 times per seconds. Pre-amplifi-
cation analogue filters are designed to prevent aliasing
so that frequency response of the acquisition is mostly
flat between 0.01 and 100 Hz. Trained neuromarkers
during NF are the following: SMR in C3 + Cz + C4 and
TBR in F3 + Fz + F4 + Cz. The software is pre-installed
on a tablet computer dedicated to the application. The
tablet is battery powered and connected to a medical
grade EEG signal amplifier, which is connected to the
EEG cap by the mean of individual actively shielded
cables protecting against common mode electromagnetic
contaminations. All elements come in a transport case
that patients take home. The application guides the user
through his session featuring headset setup, calibration,
and training protocol.
The EEG signal quality is controlled by a session-cali-
brated eye blink removal using Blind Source Separation
[35] and a signal quality index (SQI) algorithm [36], both
working in real-time to increase the training specificity
by removing noise in the signal fed back to the user.
The SQI is calibrated with data acquired in the clinic
under expert supervision thereby setting the level of
quality desired for sessions recorded in the home. The
definition of typical EEG frequency bands is personalized
to account for the discrepancies in the subjects’ brain
Table 1 Description of visits
Visit Pre-
inclusion
Inclusion Discovery or open titration Treatment period (MPH or NFB)
Initial discovery or
titration
Discovery or
titration
Discovery or
titration
Final discovery or
titration
Intermediate Final
Day D-90 to
D-1
D0 D7 ± 3 D14 ± 3 D21 ± 3 D28 ± 3 D60 ± 7 D90 ±
10
Protocol explanation X
Inform consent form X
Inclusion/exclusion criteria X
Demographic data X
Medical/surgical history X
Medical examination X
qEEG X X X
Randomisation X
MPH delivery X X X X X
NFB discovery session X X X X X
Kiddie-Sads X
ADHD RS parents X X X
ADHD RS clinician X X X
ADHD RS teacher X X
CGI-I score X X X X X X
CGI-S score X X X X X X X
C-SSRS (Columbia suicide
rating scale
X X X X X X X
SDSC X X X X X X X
SDQ by teacher/parent X X
BRIEF X X
Conners 3 CPT X X
WASI 3 subtest (or WISC less
3 months)
X
Concomitant treatments X X X X X X X
Adverse event collection
(spontaneous)
X X X X X X
PAERS questionnaire X X X X X X X
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maturation within our paediatric population. The indi-
vidualized alpha peak frequency (iAPF) is defined as the
maximum power value between 7 and 13 Hz at electrode
Pz and used to define theta (iAPF− 5 to iAPF− 1 Hz),
beta (iAPF+ 3 to iAPF-5 Hz), and SMR (iAPF+ 2 to
iAPF+ 5Hz). A qEEG assessment is first completed for
all patients in order to calibrate the SQI, the iAPF, and
determine the subject’s EEG profile. A theta/beta ratio
(TBR) exceeding 4.5 is considered significant [37]
(NCT02251743). During the initiation visit, the clinician
presents the system and the neurofeedback application
to the patient and his parents and supervises the first
“discovery” neurofeedback training session.
The NF training session consists of five four-minute-
long “active” NF blocs (with real-time feedback) and two
two-and-a-half-minute-long “transfer” blocs (with only
intermittent feedback). The total duration of a training
session remains below 30-min. Two games sharing com-
mon design principles are implemented in the application
and provided the subject with real-time rewards; the neu-
romarker activity is visualized as a moving bar and re-
wards are displayed through either a fishing of a puzzle
game. The child is able to choose between two games at
the beginning of each session. At the end of every block, a
performance report is displayed to the user.
Three types of rewards are delivered:
 Classic reward: The classic reward increments the
score on the session. The reward is obtained each
time the neuromarker activity is above (up-training
protocol) or below (down-training protocol) the
threshold for a time longer than 500 ms (time-gating
parameter). As long as the activity is maintained
above/below the threshold, the reward is provided
and the score incremented with the refreshing rate
of the game.
 Cumulative booster: The cumulative booster
commands a feedback element of the metaphor. A
reward is given when the activity below (down-
training protocol) or above (up-training protocol)
the threshold reaches 3 s of cumulated time.
 Consecutive booster: The consecutive booster
commands another element of the metaphor and
acts as an extra reward. The reward is given when
the activity is maintained below/above the threshold
of 3 s.
Before starting the NF treatment, participants have neu-
rofeedback discovery sessions. First these sessions occur at
the clinical centre (1 to 4 discovery visits). Purpose of
these meetings is to teach the child and parents how to
use the system by themselves. The clinician shows the
proceeding of a standard neurofeedback session and in-
structs the child to keep the moving bar above a certain
threshold and to gain rewards (displayed either as fish ore
treasures in the fishing game or as puzzle pieces in the
puzzle game). When the participants are sufficiently au-
tonomous to go home with the device and practice NF
without the supervision of a clinician, they can begin the
discovery sessions at home. Discovery sessions at home
give the patient the opportunity to experience neurofeed-
back sessions alone or under his parents’ supervision. It
occurs after one or several discovery visits. These sessions
are not considered in the evaluation of the treatment effi-
cacy. The number of discovery sessions performed at
home is limited to a maximum of 10.
Participants receive an installation guide of the EEG
cap and the ADHD@Home device. Each session begins
with an impedance check to control the quality of con-
tact of each electrode. The impedance is represented on
the screen by a colored electrode’s map with different
colors for good and bad contact quality.
The discovery phase ends with a “final” discovery ses-
sion at the clinic. The first treatment phase starts when
the patient is at ease with the system. Sixteeen to twenty
neurofeedback sessions at home are scheduled from the
Fig. 2 Overview of the ADHD@Home Device
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specialist interface on a specific period lasting from a
starting date, to the date of the next appointment at the
clinic. During this phase, the patient logs in the applica-
tion on average 4 times a week to complete neurofeed-
back sessions that have been prescribed to him. If he
occasionally misses sessions, he can reschedule them on
same week. Treatment resumes after the mid-assess-
ment. The patient performs another 16 to 20 prescribed
sessions at home, up to a total of 36 sessions, again with
a frequency of 4 sessions per week. In total, 36 sessions
(4 sessions per week for 9 weeks) should be done.
The specialist interface of the ADHD@Home solution
allows the clinician to know if subjects have done their
session. Clinicians have a remote follow up of patient
performances and compliance via a web portal accessible
on an Internet page. With this interface the specialist
can follow the performance, the agenda of sessions and
consult errors (connection, missing sessions,…) that
have occurred during the training at home phase. Moni-
toring occurs every week. In the event that more than 2
or more sessions, out of 4, are missed during a given
week, the clinician will call the parents of the child to
enquire about the poor compliance. The goal is to
understand the reason behind the missed sessions, to fix
any issues that arise and to motivate the child and his
parent to stick to the treatment regimen. They will be
reminded that the missed sessions can be made up in
subsequent weeks with a limit of 1 session per day.
ADHD@Home NF integrates algorithms for the
identification of artefacts - non-EEG signals such as
head movements, muscular contractions, blinks - in
order to guarantee that personalized brain rehabilita-
tion is performed based on clean brain signals. Arte-
facts interrupt the real time feedback of the software
if they cannot be corrected sufficiently by the imple-
mented artefact correction algorithms; this is dis-
played on the game by a cloud masking the sun or a
changing background colour.
Methylphenidate group
There are two periods for this group: an open titration
period and a treatment period. The open titration period
lasts 3 weeks (from D3 to D28) and consists of 4 visits.
The subject starts with 10mg/day of extended-release
methylphenidate/day. During the subsequent titration
visits, the investigator decides if the dose is increased or
not. The maximal dose is 60 mg/day. Titration is based
on clinical experience of the investigator and the com-
pleted scales, taking into account both tolerance and
risk/benefit ratio.
The treatment period lasts 2 months (from Day 28 to
Day 90). During this period, the optimal dose is
maintained.
Assessments
Physical assessment
The physical examination includes a detailed clinical his-
tory, assessments of height and weight, blood pressure,
and heart rate. Concomitant treatments are assessed in
both treatment groups.
Psychometric assessments
ADHD rating scale IV (ADHD RS IV) [30, 38] This
scale is an 18-item scale with one item for each of the
18 symptoms contained in the DSM-IV diagnosis of
ADHD: nine items make up the inattention subscale and
the other nine the hyperactivity–impulsivity subscale.
Each item is scored on a 0–3 scale. Clinician, parents
and teachers will answer this scale to evaluate attention
and hyperactivity/impulsivity.
The clinician version of ADHD Rating Scale, is a vali-
dated tool for assessing the severity of ADHD symptoms
and change in symptom severity [38].
Behavior rating inventory executive function (BRIEF)
[39] This scale is a validated and standardized instru-
ment that assesses executive functioning, including 8
subscales comprising 2 indices summed together in the
Global Executive Composite.
Strengths and difficulties questionnaire (SDQ) [40]
The SDQ is a brief behavioral screening questionnaire
assessing 25 attributes, some positive and others nega-
tive, which can be allocated to five scales (emotional
symptoms, conduct problems, hyperactivity/ inattention,
peer relationship problems, and prosocial behavior).
These scales can be summed to calculate a total difficul-
ties score with the advantage of being able to assess
short-term changes [41].
Clinical global impression (CGI) scale [42] The CGI is
a clinician-administered tool providing a scoring of ini-
tial severity on the CGI–Severity Scale (CGI-S) from 1
to 7; subsequent improvements over time during treat-
ment are rated using the improvement component
(CGI-I). During follow-up visits, clinicians use the CGI-I
7-point scale to rate the patients’ total improvement
based on comparison with their baseline assessment
from 1 = very much improved to 7 = very much worse.
Pediatric adverse event rating scale (PAERS) [43] The
PAERS detects clinically important adverse events po-
tentially but not necessary related to the drug. We will
use the PAERS clinician interview form. The question-
naire includes 43 items to be asked in a patient-friendly
language but recorded in the medical terminology. The
administration time is 10 to 15 min. The PEARS is ad-
ministered to both NF and MPH groups.
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Columbia suicide severity rating scale (C-SSRS) [44]
The Columbia–Suicide Severity Rating Scale (C-SSRS) is
designed to quantify the severity of suicidal ideation and
behaviour. Four constructs are measured: The first is the
severity of ideation (“severity subscale”), the second is the
intensity of ideation subscale (“intensity subscale”), the
third is the behavior subscale and the fourth is the lethality
subscale, which assesses actual attempts. At inclusion, the
« Lifetime/Recent version » will be used. At the other
visits, the “Since the last visit version” will be used.
Sleep disturbance scale for children (SDSC) [45] The
Sleep Disturbance Scale for Children (SDSC) is a 26
item Likert-type rating scale which evaluates specific
sleep disorders in children, and provides an overall
measure of sleep disturbance suitable for use in clinical
screening and research. Items are divided into six cat-
egories representing some of the most common sleep
difficulties affecting adolescents and children: disorders
of initiating and maintaining sleep, sleep breathing disor-
ders, disorders of arousal/nightmares, sleep-wake transi-
tion disorders, disorders of excessive somnolence, and
sleep hyperhidrosis (night-time sweating). The question-
naire is completed by a parent or caregiver on behalf of
the child. Parents use a five-point, Likert-type scale. At
the Final visit, the assessment will cover the period of
the last month, rather than the six latest months.
Attention test The Conners CPT 3 (Conners Continu-
ous Performance Test 3) [32] is a validated and stan-
dardized computerized go/no-go and attention test
measures attention and impulsivity. “Subjects have to
react to target letters on the computer screen except to
the letter X. The experiment comprises 6 blocs of 140 s
each. Each block contains 54 targets (except the block 1:
53 targets) and 6 non-targets. The task lasts for 14 min.
Participants observe computer generated letters pre-
sented at inter-stimulus intervals of 1, 2, and 4 s, with a
display time of 250 ms. Results are described with differ-
ent variables: correct hits (number of cases where a re-
sponse occurs in presence of a target), commission
errors (number of cases where a response occurs in
presence of a non-target), mean reaction time (hit reac-
tion time) and variability of hit reaction time (measured
by standard deviation). These indicators are also re-
corded for every block and group. Commission errors
are a measure of impulsivity”.
Statistics
Sample-size calculation
The primary endpoint is the change from baseline (in-
clusion visit) to end of treatment (last visit) in the Clin-
ician ADHD RS IV total score. The upper limit of the
90% confidence interval (1-sided) for the difference
between the two groups in the primary endpoint is cal-
culated. Non-inferiority is declared if the upper limit is
less than a 4.5 points difference on the primary outcome.
This non-inferiority margin comprised between half and
2/3 of the mean superiority threshold of 7.5 [46] and
below the minimally clinically relevant difference of 6.6
[38] was considered a clinically acceptable.
With a non-inferiority bound estimated at 4.5 and a
standard deviation estimated at 11.5 for the primary
endpoint, and using a 3:2 ratio, the number of subjects
required is 170. In anticipation of a 5% drop-out rate,
the total number of patients required is 179. Therefore
179 patients, 72 in the MPH group and 107 in the NFT
group will be recruited.
Statistical analysis is performed with SAS® version 9.4
or higher (SAS Institute North Carolina, USA).
Analysis
Study populations
Different populations are defined:
 The total population: all patients enrolled in the
study who signed the inform consent form;
 The modified Intent To Treat Population (mITT) /
safety population: all randomized patients from total
population who received at least one dose of
methylphenidate for MPH group or who
participated to the first neurofeedback session for
NFT group;
 The Per Protocol (PP) population: patients from the
ITT population with no major protocol deviations
(primary population);
Demographic and baseline characteristics:
Baseline characteristics will be described by treatment
group on the mITT and on the PP at D90. Both groups
will be compared as following:
– For quantitative data, a Student t-test will be
performed, or a non parametric Mann-Whitney test
if the normality hypothesis is rejected.
– For categorical data, a chi-square test will be used or
a Fisher exact test depending on the sample size.
Primary endpoint analysis
The primary endpoint is the change from baseline (inclu-
sion visit) to end of treatment (last visit) in the Clinician
ADHD RS IV total score. The upper limit of the two-sided
90% confidence interval (one-sided 0.050 significance
level) for the difference between the two groups in the pri-
mary endpoint [NFT: D90 - D0] - [MPH: D90 - D0] will
be calculated. Non-inferiority will be declared if this upper
bound is less than 4.5. Non-inferiority is declared if the
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upper limit is less than a 4.5 points difference on the pri-
mary outcome.
In case of non-homogeneity between treatment groups
at baseline, a covariance analysis (SAS® Mixed proced-
ure) will be performed on the difference D90-D0, with
the baseline index as covariate and the treatment as fac-
tor. If necessary, other covariates could be tested. A sen-
sitivity analysis including the center as covariate (SAS®
Mixed procedure) will also be performed. The same ana-
lysis will be conducted with the investigator as covariate.
This analysis will be performed on the PP population at
D90. Results on the mITT population will be given for
information purpose only. The only comparison pro-
vided for in the protocol is carried out on the main cri-
terion. For all secondary efficacy endpoints analyses,
statistical tests are given for information purpose only.
Secondary endpoint analysis
All secondary efficacy endpoints analyses will be per-
formed on the PP population and statistical tests will be
given for information purpose only. Analyses will use 2-
sided tests at the 5% significance level, except the nor-
mality tested at the threshold of 1% (Shapiro-Wilk test).
The following analyses will be performed on patients
for whom the studied endpoint is available at D0 and at
least one post-baseline evaluation.
Clinician ADHD RS IV Total, Inattention and Hyper-
activity Scores
– Parents ADHD RS IV Total, Inattention and
Hyperactivity Scores
– Teacher ADHD RS IV Total, Inattention and
Hyperactivity Scores
– Executive Function Tests by the Behavior Rating
Inventory of Executive Function (BRIEF)
– The Conners Continuous Performance Test 3rd
Edition (Conners CPT 3)
– In-school behavior by the Strengths and Difficulties
Questionnaire (SDQ) scores
– Parents Strengths and Difficulties Questionnaire
(SDQ) scores
– EEG signature evaluation including IAPF value, TBR
value and SMR value.
Groups will be compared with:
– the chi-square test for categorical variables,
– the t-test for continuous variables (or the non-
parametric Mann-Whitney test when the
assumption of normality is questionable).
Statistical tests will be 2-sided with a 0.050 significance
level.
Safety and adherence analysis:
The following numbers and percentages will be calcu-
lated and compared between the two groups: patients
who experienced at least one adverse event (on the
whole and by system/organ), at least one adverse event
leading to discontinue the treatment, and at least one
serious adverse event. All adverse events will be de-
scribed in each group.
In addition, the use of concomitant medications will
be summarized by therapeutic class using descriptive
statistics. Concomitant medications will include all med-
ications taken while the patient is treated with study
drug.
The adherence will be described in each group during
the treatment period:
– number of Neurofeedback Sessions completed for
NFT patients,
– % of observance (number of taken pills / number of
theoretical pills that should have been taken during
the treatment period) of Methylphenidate for MPH
patients.
Groups will be compared on the main baseline criteria,
the clinician and parents ADHD-RS, the presence of at
least one AE and presence of at least one ADE. Compar-
isons will follow the same methodology as described for
the MPH/NFT comparisons.
Analyses of the NF subgroups:
In the NFT subgroup from the PP population, compar-
isons will be performed on the efficacy and safety data
as following:
– Performers versus other NFT patients: a performer
shows statistically significant changes in their EEG
comparing resting state and training EEG averaged
across 46 sessions;
– Learners versus other NFT patients: a learner shows
statistically significant changes in their training EEG
over 46 sessions;
– Fast Learners versus other NFT patients: a fast
learner shows statistically significant changes in their
training EEG over first 26 sessions only (mid-
assessment);
– Transfer Learners versus other NFT patients: a
transfer Learner shows statistically significant
changes in their transfer training EEG over first 26
sessions.
These groups are defined using the longitudinal EEG
data collected by the NEWROFEED RCT data and a list-
ing of patients in each group will be provided by Mensia
Technologies. The necessary details to replicate the
identification of the exact same sub-populations can be
obtained from the promoter.
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Another comparison will be performed between Im-
provers versus non-improvers: an improver is a patient
showing a reduction of the total clinician ADHD RS
score of ≥25% from baseline.
Interim analysis
In order to monitor the EEG data quality, an interim
analysis is planned on the first 50 patients; this will also
permit us to compare the sessions at the clinic and at
home. We have defined two criteria of data quality,
which are known to affect EEG recordings:
– Electromagnetic (EM) contamination shows the
contamination by main power;
– EMG contamination are generated by face and neck
muscle.
We have also added two criteria that we believe are
specific of our application:
– Slow frontal artefacts are characteristic of patients
being given a too large EEG cap making the frontal
electrode “float”;
– The “averaged” coefficients of the blink estimation
are used to ensure that algorithms for blink
correction were fed with clean data and converged
appropriately.
Discussion
This paper presents the protocol and design of a prospect-
ive, multicentre and randomized reference drug-con-
trolled trial of NF, in children with ADHD. Innovative
aspects of the NEWROFEED study are the personalisation
of the NF training protocol according to the individual’s
TBR ratio and the at-home training sessions. This is the
first non-inferiority study between a personalized NF
training device and pharmacological treatment.
NF is a non-pharmacological strategy that involves
less complex cognitive strategies than cognitive re-
mediation or psychotherapy despite clear behavioral
and learning elements, involving physiological self
regulation and state control.
In contrast to other types of brain signal (e.g. functional
MRI), EEG provides a high temporal resolution offering
quasi immediate feedback and a fine-grained analysis of
learning mechanisms. Furthermore, EEG is less costly and
more praticle than near-infrared spectroscopy (NIRS) and
functional magnetic resonance imaging (fMRI). The EEG
recording and its modifications could also constitute a
physiological marker of ADHD and its evolution over the
course of the treatment. The current trial will enable the
assessment of non-inferiority of NF compared with stand-
ard treatment but will also evaluate the effects of NF train-
ing parameters (number and quality of sessions), and
individual characteristics (learning speed and efficiency,
transfer effects).
The presumed strengths of Mensia Koala™ are: artefact
control, personalization, and home use all of which are
targeted to improve clinical effectiveness. First, artefact
control is implemented as a twofold strategy comprised
of real time artefact correction (active shielding and eye
blink removal [35] and detection (Riemannian SQI) [36].
Artefact control ensures the user is only rewarded based
on his brain electrical activity and not on relatively high-
amplitude unrelated artefacts (including muscle activity).
It therefore prevents a subject to “cheat” by modifying
(voluntarily or not) a physiological rather than neuro-
physiological variable. Then, the personalization in Men-
sia Koala is also intended to increase therapeutic efficacy
by targeting unhealthy brain activity in a more specific
fashion. The treatment is personalized at three levels: 1)
The frequency bands for the training are personalized
based on the individual Alpha Peak Frequency (iAPF)
extracted from the patient brain activity, 2) Based on
these personalized frequency bands, a neuromarker is
automatically calculated by the software and compared
to a reference value. 3) The adequate protocol is selected
based on the computed neuromarker. First, iAPF bands
are prefered because it has been reported that the correl-
ation between the theta activity and the core symptoms
of ADHD (ADHD-RS) was stronger when the frequency
band definitions was corrected for iAPF [47]. This is par-
ticularly relevant for an ADHD pediatric population
right within the age range affected by a pathophysio-
logical brain maturation [48, 49]. Second, the NF proto-
col (SMR or TBR) is personalized in each child based on
his EEG profile. The EEG phenotype is represented with
the TBR because it was found to relate to clinical scales
of ADHD as well as performance on executive function
tests [50]. Despite failing at being used as a diagnostic
neuromarker for ADHD [16, 51], it is a promising prog-
nosis marker and has already reportedly being used as
such (NCT02251743; [37]).
The fact that Mensia Koala can be used at home is also
believed to contribute to its effectiveness mostly because
the sessions occur in a more ecological environment,
which could enhance the transfer of learned skills to real
life situations. To maintain treatment quality in this con-
text, data recorded at home is sent to a secured web portal
offering remote monitoring of sessions compliance, qual-
ity, and performance (scores and neuromarkers). Several
information are accessible through the interface in order
to follow the patient progression during the treatment:
alerts and errors logged by the application during the NF
sessions at-home, a library with all sessions’ report gener-
ated during the study accessible for consultation or
download, a statistics section with the evolution of neuro-
markers and scores across sessions.
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Other strengths of the NEWROFEED protocol are the
sample size, the multi-centre study and the collaboration
within the scientific committee of experts from the EEG
domain and clinicians involved in ADHD.
The non-inferiority design versus MPH was chosen
because, on the basis of previous studies we did not ex-
pect NF to be superior to the drug of reference and be-
cause the absence of superiority does not imply the
treatments are equivalent. Advantages of choosing MPH
as a comparator are its well documented effects across
various settings and observers [52] and its availability
(i.e. non-stimulant drugs are not available in all partici-
pating countries). It is also the first-line medication rec-
ommended in our target population [53]. However, the
evidence of non-inferiority of NF against the robust ef-
fects of MPH does require technical innovation in NF
delivery and remains a challenging issue.
A limitation of the current NEWROFEED protocol is
that clinicians were not blind to group assignment. But
due to the investigational products (pills versus NF with
EEG during serious game on tablet), this will be a non-
blinded study. It is difficult to assess children with
ADHD in blind condition. One dimension of ADHD is
impulsivity, it is difficult to conduct an interview without
the children or his parents give some information about
the treatment received (medication or neurofeedback).
Another possible limitation of the current NEWRO-
FEED protocol is the absence of sham NF. Sham NF pro-
vides feedback unrelated to actual self-regulation
performance. However, unsuccessful attempts to modulate
neural activity may result in poor compliance and negative
emotions incompatible with an optimal placebo condition.
Apart from the ethical issues, the feasibility of a sham con-
dition for neurofeedback is doubtful because it is likely to
be detected [54] and because the first stage of the NFB
learning process requires conscious control over the target
variable [55]. We therefore compare NF to standard med-
ical treatment with methylphenidate but include probably
blinded assessments by teachers [6, 8, 10] and an objective
attentional assessment by means of the CPT, a measure-
ment sensitive to treatment effects [56]. Another limita-
tion of our protocol is the lack of systematic follow up
assessment given the relevance of long term effects ex-
pected for neurofeedback [57].
More generally, the implementation of NF also faces
other challenges such as the necessity to provide a suffi-
cient evidence-base for new treatments, appropriate
training of clinicians, monitoring by accredited organisa-
tions and lastly, reimbursement possibilities for treat-
ments meeting quality and efficacy criteria.
In conclusion, this trial is the first protocol and design
of a prospective, multicentre and randomized reference
drug-controlled trial in children with ADHD, using a
personalized NF training device at home.
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